Literature DB >> 27330071

Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints.

Femke de Velde1, Brenda C M de Winter2, Birgit C P Koch3, Teun van Gelder4, Johan W Mouton5.   

Abstract

OBJECTIVES: To describe the population pharmacokinetics of oral amoxicillin and to compare the PTA of current dosing regimens.
METHODS: Two groups, each with 14 healthy male volunteers, received oral amoxicillin/clavulanic acid tablets on two separate days 1 week apart. One group received 875/125 mg twice daily and 500/125 mg three times daily and the other group 500/125 mg twice daily and 250/125 mg three times daily. A total of 1428 amoxicillin blood samples were collected before and after administration. We analysed the concentration-time profiles using a non-compartmental pharmacokinetic method (PKSolver) and a population pharmacokinetic method (NONMEM). The PTA was computed using Monte Carlo simulations for several dosing regimens.
RESULTS: AUC0-24 and Cmax increased non-linearly with dose. The final model included the following components: Savic's transit compartment model, Michaelis-Menten absorption, two distribution compartments and first-order elimination. The mean central volume of distribution was 27.7 L and mean clearance was 21.3 L/h. We included variability for the central volume of distribution (34.4%), clearance (25.8%), transit compartment model parameters and Michaelis-Menten absorption parameters. For 40% fT>MIC and >97.5% PTA, the breakpoints were 0.125 mg/L (500 mg twice daily), 0.25 mg/L (250 mg three times daily and 875 mg twice daily), 0.5 mg/L (500 mg three times daily) and 1 mg/L (750, 875 or 1000 mg three times daily and 500 mg four times daily).
CONCLUSIONS: The amoxicillin absorption rate appears to be saturable. The PTAs of high-dose as well as twice-daily regimens are less favourable than regimens with lower doses and higher frequency.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27330071     DOI: 10.1093/jac/dkw226

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin.

Authors:  Marina Becker Sales Rocha; Gilberto De Nucci; Francisco Ney Lemos; Rodrigo Feitosa de Albuquerque Lima Babadopulos; Andrea Vieira Pontes Rohleder; Francisco Vagnaldo Fechine; Natalícia J Antunes; Gustavo D Mendes; Demetrius Fernandes do Nascimento; Manoel Odorico de Moraes; Maria Elisabete Amaral de Moraes
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

2.  Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.

Authors:  Anne Fournier; Sylvain Goutelle; Yok-Ai Que; Philippe Eggimann; Olivier Pantet; Farshid Sadeghipour; Pierre Voirol; Chantal Csajka
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers.

Authors:  Dominique Vodovar; Laure Thomas; Nicolas Mongardon; Raphaël Lepeule; Bénédicte Lebrun-Vignes; Michel Biour; Florence Netzer; Hakim Haouache; Christine Le Beller; Gilles Dhonneur
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

4.  Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux-en-Y gastric bypass bariatric subjects.

Authors:  Maiara Camotti Montanha; Thiago Ferreira Dos Santos Magon; Conrado de Souza Alcantara; Caroline Ferraz Simões; Sandra Regina Bin Silva; Cristina Megumi Kuroda; Sérgio Seiji Yamada; Lucas Eduardo Savóia de Oliveira; Daoud Nasser; Nelson Nardo Junior; Josmar Mazucheli; Andrea Diniz; Paulo Jorge Pereira Alves Paixão; Elza Kimura
Journal:  Br J Clin Pharmacol       Date:  2019-07-12       Impact factor: 4.335

5.  Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.

Authors:  Julia A Bielicki; Wolfgang Stöhr; Sam Barratt; David Dunn; Nishdha Naufal; Damian Roland; Kate Sturgeon; Adam Finn; Juan Pablo Rodriguez-Ruiz; Surbhi Malhotra-Kumar; Colin Powell; Saul N Faust; Anastasia E Alcock; Dani Hall; Gisela Robinson; Daniel B Hawcutt; Mark D Lyttle; Diana M Gibb; Mike Sharland
Journal:  JAMA       Date:  2021-11-02       Impact factor: 56.272

6.  A novel PBP3 substitution in Haemophilus influenzae confers reduced aminopenicillin susceptibility.

Authors:  John Thegerström; Erika Matuschek; Yu-Ching Su; Kristian Riesbeck; Fredrik Resman
Journal:  BMC Microbiol       Date:  2018-05-31       Impact factor: 3.605

7.  Amoxicillin Administration Regimen and Resistance Mechanisms of Staphylococcus aureus Established in Tissue Cage Infection Model.

Authors:  Qian Yao; Linglin Gao; Teng Xu; Yun Chen; Xin Yang; Mengmeng Han; Xiaotao He; Chengheng Li; Ruigang Zhou; Yuhui Yang
Journal:  Front Microbiol       Date:  2019-07-22       Impact factor: 5.640

8.  Two versus five days of antibiotics after appendectomy for complex acute appendicitis (APPIC): study protocol for a randomized controlled trial.

Authors:  Anne Loes van den Boom; Elisabeth M L de Wijkerslooth; Joost van Rosmalen; Frédérique H Beverdam; Evert-Jan G Boerma; Marja A Boermeester; Joanna W A M Bosmans; Thijs A Burghgraef; Esther C J Consten; Imro Dawson; Jan Willem T Dekker; Marloes Emous; Anna A W van Geloven; Peter M N Y H Go; Luc A Heijnen; Sander A Huisman; Dayanara Jean Pierre; Joske de Jonge; Jurian H Kloeze; Marc A Koopmanschap; Hester R Langeveld; Misha D P Luyer; Damian C Melles; Johan W Mouton; Augustinus P T van der Ploeg; Floris B Poelmann; Jeroen E H Ponten; Charles C van Rossem; Wilhelmina H Schreurs; Joël Shapiro; Pascal Steenvoorde; Boudewijn R Toorenvliet; Joost Verhelst; Hendt P Versteegh; Rene M H Wijnen; Bas P L Wijnhoven
Journal:  Trials       Date:  2018-05-02       Impact factor: 2.279

9.  Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

Authors:  Marlieke E A de Kraker; Harriet Sommer; Femke de Velde; Isaac Gravestock; Emmanuel Weiss; Alexandra McAleenan; Stavros Nikolakopoulos; Ohad Amit; Teri Ashton; Jan Beyersmann; Leonhard Held; Andrew M Lovering; Alasdair P MacGowan; Johan W Mouton; Jean-François Timsit; David Wilson; Martin Wolkewitz; Esther Bettiol; Aaron Dane; Stephan Harbarth
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

10.  A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis.

Authors:  J W S Cattrall; E Asín-Prieto; J Freeman; I F Trocóniz; A Kirby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.